Q-omics provides the consensus-scored XKR3 profile across patient tissues and cancer cell-line models. XKR3 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, XKR3 is differentially expressed in 8, with the highest sampling consensus in KIRP. Additionally, XKR3 RNA expression shows 6,765 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LUSC, KIRP, and STAD as cancer lineages where XKR3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for XKR3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes XKR3 survival associations across molecular data types. XKR3 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible XKR3 RNA expression–survival associations across cancer types. High XKR3 expression shows unfavorable associations in LUSC, READ, MESO, THCA and SCLC, but favorable associations in HNSC. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for XKR3 RNA expression.
This table summarizes XKR3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for XKR3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. XKR3 shows lower tumor expression in LUSC, PAAD and LUAD and higher tumor expression in KIRP, KIRC and LIHC. The KIRP box plot shows higher XKR3 RNA expression in tumor versus normal tissue (log2 FC = +0.692, t-test p < 0.001).
This table shows molecular features associated with XKR3 in patient tissues and cancer cell lines. In patient samples, XKR3 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, XKR3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
